A fter bioresorbable scaffold (BRS) implantation, vessel wall support and lumen patency are maintained while device dismantling occurs over time. 1, 2 Recent reports indicate that early BRS dismantling may result in intraluminal strut protrusion, 3 and it may be responsible for target vessel failure 4 and very late scaffold thrombosis. 5 Then, maintaining a stable scaffold's architecture through the device's degradation process is key to achieve long-term vessel patency and positive clinical results. Current-generation BRS use highly crystalline poly-l-lactic acid (PLLA), and they have been extensively studied in the experimental and clinical setting. 1,6-8 These first-generation BRS technologies rely on polymer crystallinity to achieve mechanical strength resulting in limited overexpansion capabilities and structural integrity when exposed to high loading conditions. A novel ultrahigh-molecular-weight amorphous PLLA BRS (Fortitude, Amaranth Medical, Mountain View, CA) display higher elongation at break points and promise to enhance the biomechanical properties of BRS by overcoming these limitations. The long-term in vivo biocompatibility of the polymer and biomechanical properties of this particular scaffold have been already tested in the absence of antiproliferative drugs in animals (3 years) 9 and humans (2 years; J.F. Granada, MD, unpublished data, 2016).
Novel Sirolimus-Eluting BRS sirolimus-eluting BRS (Amaranth BRS) against the clinically available Absorb bioresorbable vascular scaffold (BVS) using different experimental models.
Methods

Device Description
The Fortitude Amaranth BRS is manufactured using an ultrahigh-molecular-weight bioresorbable polylactide-based polymer with strut thickness of 150 µm and incorporates 3 platinum radioopaque markers at both ends to improve angiographic visualization. The Amaranth BRS is coated with a matrix consisting of 1:1 polymer: drug ratio of sirolimus plus poly d-lactide polymer and has a drug dosing of ≈ 96 µg/cm 2 . The core Amaranth BRS technology involves a proprietary process of ultra-high-molecular-weight polymer synthesis and processing designed to achieve a balance between strength, flexibility, and high resistance to fracture. Tube manufacturing is achieved by a proprietary multilayer deposition process. The biomechanical properties of the polymer are fully preserved throughout the manufacturing cycle with negligible reduction of molecular weight and no alteration of thermal properties from PLLA tubing fabrication to the final sterile device. In vitro studies showed that the scaffold degrades over time and the reduction in molecular weight reach ≈50% of the initial molecular weight at 8 months and >85% at 18 months. The radial support is maintained for ≈8 to 10 months. In vitro vessel wall surface coverage analysis performed using light microscopy (40×) has demonstrated that the Amaranth BRS has ≈21% to 25% vessel surface coverage depending on the scaffold diameter (2.5-3.5 mm).
In the current study, the Fortitude sirolimus-eluting Amaranth BRS (150 µm) was compared with a CE (Conformité Européenne)approved, commercially available Absorb everolimus-eluting BVS (version 1.1; Abbott Vascular, Santa Clara, CA). The Absorb BVS is a balloon-expandable, fully bioresorbable scaffold that consists of a poly (l-lactide) backbone with strut thickness of 150 µm and a poly (d, l-lactide) coating in a 1:1 ratio with everolimus doses of 100 µg/cm 2 .
In Vitro Overexpansion and Cyclic Fatigability Testing
The mechanical behavior of the Amaranth BRS and Absorb BVS following overexpansion was examined under static conditions. Both Amaranth BRS (2.75 mm) and Absorb BVS (3.0 mm) scaffolds were deployed in vitro at their rated burst pressure (16 atm Absorb BVS, 15 atm Amaranth BRS) following the recommended dilatation technique. The scaffolds were then postdilated using commercially available balloon catheters until strut fracture was observed. The scaffolds were additionally inspected at ≈0.5-mm-diameter increments using conventional light microscope techniques (AmScope, Irvine, CA). Measurements were performed using a calibrated measurement gauge to measure the scaffold outer diameter. In addition, mechanical stability over time was tested under dynamic load conditions. In this study, fracture resistance was evaluated by applying identical multimodal cyclic loads to the scaffolds ( Figure 1 ). The cyclic loads were similar to conditions present in physiological environments but with 50% to 100% greater amplitude to highlight mechanical properties of the scaffolds.
In Vivo Animal Study
A summary of the in vivo study design is illustrated in Figure 2 . The Institutional Animal Care and Use Committee approved this study, and all animals received care in accordance with the Guide to Care and Use of Laboratory Animals. Eighteen Yucatan mini swine (49.0±13.7 kg) were used in cohort 1 for biological efficacy evaluation; and 19 swine (46.6±12.8 kg) were used in cohort 2 for pharmacokinetic studies. Dual antiplatelet therapy consisting of oral clopidogrel (75 mg) and aspirin (325 mg) was initiated the day before the procedure and maintained throughout the study. All animals received intramuscular Telazol (4 mg/kg) and Glycopyrrolate (0.004-0.02 mg/kg) injections for induction and antimuscarinics for intubation. All animals were maintained on a continuous inhalation of 1% to 3% isoflurane. Anticoagulation with heparin was achieved during the procedure (500-5000 U) to maintain an activated clotting time of ≥250 seconds. Intracoronary nitroglycerin (50-200 µg) was administered to prevent or relieve vasospasm. Either Amaranth BRS (size 2.5, 2.75, 3.25, or 3.5 ×18 mm) or Absorb BVS (size 2.5, 3.0, or 3.5×18 mm) were implanted targeting a stent-to-artery ratio of 1.1:1 under intravascular ultrasound guidance. Angiography and optical coherence tomography (OCT) were performed immediately after implantation. Follow-up angiography and OCT were performed at 28, 90, and 180 days after implantation in animals used for histomorphometric analysis (n=8 for Amaranth BRS and n=6 for Absorb BVS for each time point). A second cohort of 19 animals implanted with 41 BRS and 16 Absorb BVS was designed for tissue and blood pharmacokinetic studies.
Pharmacokinetic Study
The pharmacokinetic profile of the Amaranth BRS was evaluated in 16 Yucatan mini swine (32 Amaranth BRS and 16 Absorb BVS) at 1, 7, 28, and 90 days using the liquid chromatography-mass spectrometry method by Agilux Laboratories (Natick, MA). The percentage of drug released from the scaffold at each time point was determined by measuring the residual total content on the explanted stents. The sirolimus concentration in whole blood was evaluated in 3 pigs with 9 Amaranth BRS. Blood samples were collected at 1, 2, 3, 4, 5, and 30 minutes, 1, 6, 24, and 72 hours, and 7 days post implant. The sirolimus concentration in the collected blood samples was determined using the liquid chromatography-mass spectrometry method. A pharmacokinetic analysis of sirolimus blood concentration over time data was performed using the noncompartmental model of Phoenix WinNonlin
WHAT IS KNOWN
• Randomized controlled trials have established the clinical performance of Absorb bioresorbable vascular scaffold compared with metallic everolimuseluting stents.
• These studies suggest that long-term target vessel revascularization rates are comparable between both devices; however, stent thrombosis rates seem to be slightly higher in the bioresorbable vascular scaffold group.
• Absorb bioresorbable vascular scaffold rely on polymer crystallinity to achieve mechanical strength resulting in limited overexpansion capabilities and structural integrity when exposed to high loading conditions.
WHAT THE STUDY ADDS
• New-generation poly-l-lactic acid (PLLA)-based polymers promise to improve the mechanical performance of first-generation bioresorbable scaffold (BRS). In this study, in vitro and in vivo data demonstrated a higher acute overexpansion capacity, mechanical strength under stress conditions, and healing profile of a novel sirolimus-eluting ultrahigh-molecular-weight amorphous PLLA BRS.
• This novel BRS concept has the potential to improve the performance of current-generation BRS and provide the ideal platform for the future miniaturization of the technology. Version 6.3 software (Pharsight Corporation, St Louis, MO). Porcine organ tissues (myocardium, liver, kidney, lung, and spleen) samples were collected on 28, 90, and 180 days post treatment.
Quantitative Coronary Angiography
Quantitative coronary angiography analysis was performed using QAngio XA Software 7.1.14.0 (Medis Medical Imaging System, Leiden, The Netherlands). The outer diameter of the contrast-filled catheter was used as the calibration standard and the minimum lumen diameter was obtained from the single worst view while the reference vessel diameter was automatically calculated by the interpolation method. The percent diameter stenosis was calculated from the minimum lumen diameter and the reference vessel diameter. Acute absolute and percentage scaffold recoil was defined as the difference between mean diameter of the scaffold delivery balloon at the highest pressure at implantation (X) and mean luminal diameter of stented segment after implantation (Y). Percent acute recoil was calculated as (X−Y)/X×100. 10 
OCT Imaging
OCT images were recorded using the Ilumien PCI Optimization System (St Jude Medical, St Paul, MN) and the qualitative analyses were performed with the commercial software (Ilumien Optis, St Jude Medical, St. Paul, MN). The following cross-sectional parameters were measured after calibration: the lumen area, the inner and outer scaffold area. Percentage area of stenosis (%AS) was calculated as=(1−[lumen area/inner scaffold area])×100. Neointimal thickness (NIT) was measured as the distance from the inner surface of the scaffold struts to the luminal border. Absolute and percentage late recoil was calculated as previously described. 11
Histological Analysis
An independent pathology laboratory (Alizee Pathology, LLC Thurmont, MD) conducted the histomorphometric analysis. All vessel segments were prepared, and the cross-sectional areas and the NIT was measured as previously described. 1 Vessel injury score was scored according to the method by Schwartz et al. 12 Neointimal inflammation (0-4) and fibrin deposition (0-3) were semiquantitatively scored for each section as previously descripted. 13 Endothelialization was evaluated according to the percentage of neointimal endothelial coverage (0=≈25%, 1=≈25% to 50%, 2=≈50% to 70%, 3=≈70% to 95%, and 4=≈>95%). The neointima maturity was evaluated under the following semiquantitative score: 0=not present; 1=light dispersed smooth muscle population; 2=heavier population throughout less than the entire thickness of the neointima; and 3=dense population throughout the entire thickness of the neointima.
Statistical Analyses
Statistical analyses were performed using SAS statistical software (version 9.4; SAS Institute Inc, NC). Normally distributed parametric data were expressed as mean±SD with the median and interquartile range used for variables with non-normal distributions. A mixed model was used to compare differences between the 2 treatments (Amaranth BRS and BVS) and 3 time points (1, 3, and 6 months) because data in multiple sections were not independent. Furthermore, this model contained a random effect to account for multiple scaffolds implanted in the same pig. Scheffe post hoc test was applied to compare differences between time points and differences between treatments at each time point. A nonparametric test was used for those dependent variables with non-normal distributions. All tests were 2 tailed with a significance level of P≤0.05.
Results
In Vitro Overexpansion and Cyclic Fatigability Study
In static conditions, none of the devices tested presented signs of structure fracture when overexpanded at 0.5 mm above nominal pressure (≈17% overexpansion). In the Absorb BVS group, 6.0 (5.0-10.5) fractures were seen when expanded at ≈1.0 mm above nominal diameter (≈34% overexpansion). No presence of fractures was seen on light microscopy on Amaranth BRS at 48% overexpansion (1.3 mm above nominal); 1.0 (1.0-1.5) fracture was observed at 149% overexpansion (4.0 mm above nominal; Figure 1B Figure 1A ). Figure 1B shows the overexpansion capabilities of the Amaranth BRS by allowing overexpansion of the scaffold structure during simulated side branch postdilatation procedure.
Pharmacokinetic Study
The results of the pharmacokinetics are summarized in Figure 3 . The Amaranth BRS had a drug release profile comparable with the Absorb BVS ( Figure 3A ). The mean cumulative percentage of sirolimus released during the first 28 days was 75%, with 36% being released during the first 24 hours and about 91% of the drug released at 90 days. The result of sirolimus concentration in whole blood was shown in Figure 3B . Peak drug concentrations in blood were observed at 0.5 to 1 hour post implant, and the average of maximum concentration (Cmax) of sirolimus was 3.07±0.42 ng/mL (range, 2.58 to 3 .26 ng/mL). The blood levels of sirolimus quickly declined to below the limit of quantification (<0.02 ng/mL) after 7 days ( Figure 3B ). Average terminal half-life is estimated to be 39 hours. Sirolimus in the myocardium, lungs, kidneys, spleen, and liver was below the limit of quantification after 28 days from implantation.
In Vivo Porcine Healing Study
Quantitative Coronary Angiography Analysis
At the time of device implantation, all scaffolds were overexpanded to the calculated balloon-to-artery ratio and were angiographically apposed to the vessel wall. No postdilatation was necessary in any of the implanted scaffolds. The mean balloon-to-artery ratios were comparable between Amaranth BRS and Absorb BVS (1.13±0.08 versus 1.19±0.09; P=0. 22 ).
There were no differences in the postimplant minimum lumen diameter and reference vessel diameter between 2 devices. Postimplantation absolute recoil of Amaranth BRS (0.01±0.16 mm) was slightly lower than Absorb BVS (0.07±0.18 mm; P=0.33). The postimplantation percent recoil demonstrated the same trend (Amaranth BRS 0.02±4.99% versus Absorb BVS 2.00±5.64%; P=0.28). Late lumen loss and percent diameter stenosis were comparable between both devices at all time points. There were no differences in minimum lumen diameter, percent diameter stenosis, and late lumen loss for both Amaranth BRS and Absorb BVS at any of the time points (Table 1 ). Figure 4 summarizes the in vivo OCT analysis. There were no differences in the postimplant scaffold area (Amaranth BRS 6.29±1.46 versus Absorb BVS 6.69±1.71; P=0.45) and Figure  4 ), whereas no difference was observed at 1 or 6 months. There were no differences in NIT, neointimal area, and %AS between Amaranth BRS and Absorb BVS at any time point (Figure 4 ).
In Vivo OCT Analysis
Histological Analysis
A summary of the histomorphometric analysis is shown in Table 2 and Figure 5 . Light microscopic assessment revealed that vascular responses to Amaranth BRS were comparable with those to Absorb BVS at all time points ( Figure 6 ). Neither Amaranth BRS nor Absorb BVS showed evidence of luminal thrombosis of either the main or the side branch of coronary arteries. Morphometric analysis showed no changes in internal elastic lamina or external elastic lamina area for both devices from 1 to 6 months, whereas NIT and %AS were significantly increased from 1 to 3 months in both devices. Amaranth BRS showed comparable lumen area, NIT, and %AS to Absorb BVS at all time points ( Figure 5 ). At 1 month, no peristrut or neointimal inflammation was seen in the Amaranth BRS; a low level of peristrut inflammation was noted in the Absorb BVS group at the same time point (P=0.03). Peristrut inflammation was mostly composed of eosinophils, lymphocytes, histiocytes, and occasional foreign body giant cells oriented surrounding struts and within the media/adventitia ( Figure 6) . At 3 and 6 months, the inflammatory scores were low (median scores <0.40) in both the Amaranth BRS and the Absorb BVS groups. At this time point, foreign body giant cells lining the edges of scaffold struts were seen in both device groups; the number of these cells was small and did not meet the threshold level for peristrut-associated inflammation. Injury scores were low for both devices, and no significant differences were seen in all time points. The neointima was described as immature with variable amounts of fibrin deposition (Amaranth BRS 2.00 versus Absorb BVS 1.84; P=0.81) at 1 month for both devices; by 3 months, the neointima was completely mature and rarely contained small deposits of fibrin. Percent uncovered struts was 8.04% for Amaranth BRS at 1-month and 6.17% for Absorb BVS (P=0.18). The struts were completely covered at 3 months in both devices (P=0.33).
Discussion
In this study, we aimed to evaluate the biomechanical properties, pharmacokinetic profile, and in vivo healing response of a novel ultra-high-molecular-weight amorphous PLLA BRS compared with the commercially available BVS. The major comparative findings of this study in regard to the Amaranth BRS are (1) a higher (≈48%) acute overexpansion capacity and mechanical strength of the scaffold under stress conditions, (2) a lower in vivo scaffold recoil rate over time, and (3) comparable drug release profile and healing and inflammatory responses as compared with Absorb BVS. In current-generation BRS, the level of polymer crystallinity determines the biomechanical properties of the device. In turn, polymer crystallinity is related to the polymer's molecular weight and to the process used for the manufacturing of the polymeric tube. Although current-generation BRS have achieved an acute biomechanical performance compared with metallic stents, they are still limited by their capacity to overexpand beyond predetermined limits and to resist vascular recoil under extreme conditions. 14 New-generation PLLA polymers promise to improve the biomechanical properties of current-generation BRS. These polymers have been designed to improve the biomechanical behavior of PLLA by largely depending on the intrinsic material properties instead of purely polymer crystallinity. In this study, we demonstrated that ultra-high-molecular-weight amorphous polymers dramatically improved resistance to fracture under static and dynamic conditions. In general, the Amaranth BRS can be effectively overexpanded ≤48% without evidence of mechanical failure. Also, the in vivo analysis demonstrated that the scaffold structure was better maintained over time compared with Absorb BVS. These differences are critically important in clinical situations in which BRS overexpansion is clinically indicated (ie, side branch access). One of the main challenges of BRS has been their limited ability to resist vessel recoil over time and under extreme loading conditions. Although clinically available BRS display acute radial forces comparable to metallic stents in ex vivo testing, their ability to maintain lumen stability under specific biological conditions (ie, calcium) has been challenged. 15 Optimal BRS design should ensure not only proper acute lumen gain but also sustained lumen patency as the vessel heals. Early clinical reports suggest that early scaffold dismantling resulting in intraluminal strut protrusion may be responsible for target vessel failures and scaffold thrombosis. 4, 5 The optimal time course for the in vivo degradation of BRS remains a topic of an ongoing debate. Data from patients undergoing percutaneous coronary angioplasty suggest that scaffold support for the arterial wall is required for at least 3 to 4 months. 16 Experimental data using a poly-dl-lactic acid drug-free BRS in a porcine model showed that a BRS displaying a rapid degradation profile (molecular weight loss ≈86% at 6 months) presented similar healing profiles compared with bare metal stent at 6 months. 17 However, clinical data suggest that rapid polymer absorption reduces radial force of the scaffold prematurely, which can lead to late recoil and adverse clinical events 18 ; moreover, in the clinical setting, a longer resorption period (6-9 months) may provide a more stable device dismantling process and better clinical outcomes. The BRS tested in the present study is made of PLLA struts of 150 µm thickness that are arranged in a zigzag helical design and had a peak circumferential radial force of ≈0.11 MPa, similar to metallic stents right after deployment. 18 Ex vivo degradation and in vivo data demonstrated that the radial support is maintained for ≈8 to 10 months at which time the molecular weight was reduced by ≈50%. Also, because of the particular polymer characteristics of the device tested, the radial force values displayed over time were maintained at a significantly higher level compared with Absorb BVS. It is important to highlight that all Amaranth BRS have attempted to compensate for the inherent mechanical limitations of PLLA by increasing strut width (strut footprint) and total scaffold surface area. In its present form, Absorb BVS is in the range of 26% to 32% vessel coverage area. 19 Conversely, Amaranth BRS has achieved comparable mechanical properties but maintaining lower vessel coverage area (21%-25%) in all devices ranges (2.5-3.5 mm).
In our study, the postimplantation acute scaffold recoil of the Amaranth BRS was 0.02±4.99%, which tended to be lower than Absorb BVS (2.0±5.6%). In the Amaranth BRS group, there was no scaffold area decrease during follow-up. Conversely, the Amaranth BRS's scaffold area increased at 3 (late absolute recoil: −0.50±0.72 mm 2 ) and 6 months (absolute recoil: −0.16±0.16 mm 2 ). In contrast, the Absorb BVS scaffold's area decreased at the same time points and displayed higher late absolute and percent recoil rates (Figure 4) . Then, the ex vivo and in vivo results presented here demonstrate that the Amaranth BRS display not only superior postprocedural biomechanical performance but long-term architectural stability compared with Absorb BVS.
Our pharmacokinetic results are comparable to other in vivo studies reporting that in porcine models, systemic peak levels of sirolimus reach 2.63 ng/mL at ≈1 hour after sirolimus-eluting stent implantation. 20 Only minimally detectable systemic drug levels were present beyond 7 days. 21 In the present study, the peak concentration of sirolimus in blood occurred 0.5 to 1 hour (3.07±0.42 ng/mL) post Amaranth BRS implant and quickly declined to below the limit of quantification (<0.02 ng/mL) after 7 days. The systemic pharmacokinetic profile of the Amaranth BRS was comparable to the sirolimus-eluting stent system widely characterized in animal models 20 and clinical studies. 21 In addition, the tissue pharmacokinetic analysis showed that the Amaranth BRS releases 75% of the drug by 28 days and ≈90% of the drug is released by 90 days, which was comparable to the drug release profile of the everolimus-eluting Absorb BVS ( Figure 3A ).
An important objective of this study was the evaluation of vascular healing after the implantation of the Amaranth sirolimus-eluting BRS. Previous animal and human studies have proven the polymer biocompatibility and mechanical integrity of the scaffold used in this study in the absence of sirolimus. In the porcine model, polymer biocompatibility, dismantling stability, and vessel wall remodeling have been studied with serial OCT imaging ≤3 years. 9 In addition, a small human study showed absence of restenosis and evidence of expansive vascular remodeling by angiography and OCT in 13 patients receiving bare Amaranth BRS at 2 years. In animal studies, the vascular healing profile of BVS is comparable to secondgeneration DES but usually displays slightly higher levels of peristrut inflammation early on likely related to the initial phases of polymer degradation and resorption. 1 In this study, the Amaranth sirolimus-eluting BRS displayed a comparable vascular responses to Absorb BVS at all time points; absent to mild peristrut inflammation was seen at all time points. Similarly, small peristrut fibrin deposits were initially observed in both BRS groups peaking at 1 month and rapidly decreasing to complete absorption at 3 months ( Table 2 ). The comparable degree of peristrut fibrin deposition is attributable to the similarity in drug release kinetics between the 2 BRS groups as shown in the described pharmacokinetic profiles. It is also known that fibrin degradation products can induce smooth muscle cell migration and proliferation. Endothelial cell coverage of the scaffold surface was nearly complete at 1 month (8.04% uncovered struts at 1 month and 0% at 3 months) without evidence of thrombosis. Also, there were no differences in NIT or %AS as compared with Absorb BVS at any time point in either in vivo imaging or histopathology analysis. In general, the neointima was thin, immature, and encapsulating the peristrut fibrin deposits in both BRS groups at 1 month. After that time point, drug releases slow down, leading to fibrin deposit absorption, progressive neointimal maturation, and endothelial cell coverage ( Table 2) .
The present study has some limitations that are important to discuss. First, the study was performed in healthy coronary arteries in the swine model of restenosis. All scaffolds were implanted in the main coronary artery segments avoiding large side branches (>2.0 mm). Therefore, although our data supports the safety and biocompatibility of the device, our findings cannot predict its clinical performance among patients with high atherosclerotic burden. In addition, although the 6-month follow-up period presented in this study is sufficient to test the performance and safety of the device, 22 a longer follow-up period is required to evaluate the impact of polymer resorption on vascular healing and remodeling. However, because of the similarities in sirolimus pharmacokinetics and superior mechanical performance of the Amaranth BRS, the long-term results are not expected to be inferior compared with what has been already published with Absorb BVS.
In conclusion, our data indicate that the novel sirolimuseluting Amaranth BRS used in the present study demonstrated enhanced biomechanical performance but comparable vascular healing responses to Absorb BVS, maintaining vessel lumen stability during the 6-month follow-up period. Our study contributes to the BRS literature as it introduces a novel polymeric BRS platform and tests its biomechanical performance, pharmacokinetics, and vascular biocompatibility against a clinically available BRS control. These findings are also relevant as the enrollment of the first-in-man study (n=63), and 9-month angiographic and OCT follow-up using this particular device has been already completed (JF Granada, MD, unpublished data, 2016). Finally, our findings suggest that the novel BRS tested in this study has the potential to improve the performance of current-generation BRS by providing a highly biocompatible and mechanically durable platform with the potential to miniaturize the strut thickness over time. 
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